Promising Results from DeLLphi-303: Safety and Survival in Extensive-Stage Small Cell Lung Cancer
Clinical trial results reveal an acceptable safety profile and unprecedented survival rates in patients with extensive-stage small cell lung cancer treated with tarlatamab combined with anti-PD-L1 therapy, marking a significant advance in lung cancer research.
Recent clinical findings from the Phase Ib DeLLphi-303 trial highlight the safety and efficacy of combining tarlatamab with anti-PD-L1 therapy as a first-line maintenance treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). Presented by Dr. K.G. Paulson from the Providence-Swedish Cancer Institute at the 2025 WCLC in Barcelona, the study underscores significant advancements in survival outcomes for this patient group.
Tarlatamab is a bispecific T-cell engager designed to mobilize immune cells against cancer cells expressing delta-like ligand 3 (DLL3). Previous research demonstrated its potential to extend overall survival in second-line SCLC settings. Building on this, investigators assessed its safety and effectiveness when used alongside immune checkpoint inhibitors, atezolizumab or durvalumab, in the first-line maintenance phase.
The trial enrolled 88 patients who had previously responded to four to six cycles of platinum-etoposide chemotherapy combined with anti-PD-L1 therapy. Patients began maintenance therapy within eight weeks of completing chemotherapy, receiving tarlatamab intravenously every two weeks, combined with either atezolizumab or durvalumab every four weeks until disease progression.
After a median follow-up of 18.4 months, the median overall survival was an impressive 25.3 months, with median progression-free survival of 5.6 months. The safety profile was manageable, with cytokine release syndrome (predominantly grade 1) occurring in 56% of patients, and immune-related neurotoxicity in 6%. Importantly, adverse events decreased over time, indicating long-term tolerability.
Lead researcher Dr. Paulson emphasized, "The combination of tarlatamab with anti-PD-L1 therapy offers a promising and manageable approach, showing unprecedented survival in ES-SCLC patients." These promising results support the ongoing Phase III DeLLphi-305 trial, which aims to further validate this combination therapy as a standard first-line treatment option.
This breakthrough underscores the potential of innovative immunotherapy strategies to improve outcomes for patients with aggressive lung cancers.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Resting Brain Activity May Reveal Indicators of Alzheimer's Disease Progression and Early Diagnosis
New research indicates that brain activity during rest, particularly neural flexibility, may serve as an early indicator of Alzheimer's disease and help predict its progression.
Global Health Research Gaps Narrow, but Risks of Future Divergence Loom
A recent study reveals that while progress has been made in aligning global health research with disease burdens, risks of widening gaps—especially in non-communicable diseases—pose future challenges. Funding and collaboration are key to addressing these issues.
Advances in Cilia Protein Mapping Enhance Understanding of Rare Pediatric Diseases and Genetic Disorders
New research mapping primary cilia proteins provides critical insights into their role in rare childhood diseases and genetic disorders, opening new pathways for diagnosis and treatment.
Understanding Common Causes of Stomach Pain in Children
Explore the common causes of stomach pain in children, including constipation, food sensitivities, infections, stress, and motility disorders, and learn when to seek medical help.